New hope for AML patients: drug combo shows promise in early trial
NCT ID NCT03709758
First seen Jan 18, 2026 · Last updated May 09, 2026 · Updated 20 times
Summary
This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and tolerable for people newly diagnosed with acute myeloid leukemia (AML). About 50 adults will receive the combination during initial treatment and follow-up cycles. The goal is to find the best dose and gather early information on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.